Journal article · 2026 · Open access

Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study

Buze Chala, Lucien Platon, Yssimini Nadège Guillène Tibiri, Pierre-Emeric Strubel, Lucas Thiebaut, Alioune Wade, Emmanuelle Caspar, Allan Muller, Marie Bastien, Helen Nigussie, Qingfeng Zhang, Jun Cao and 5 more

The Lancet Infectious Diseases · Published 1 August 2026 · DOI 10.1016/s1473-3099(26)00301-4

Open full textCite this paper

In brief

“Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study” is a 2026 journal article by Buze Chala and 16 co-authors, published in The Lancet Infectious Diseases. OpenAlex counts 4 citations as of 18 November 2026, which puts it in the top 3% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Infectious Diseases.

Citations
4
Most cited in
2026 (4)
Field-weighted impact
17.92
References
25
Authors
17

Abstract

Background Artemisinin partial resistance (ART-R) has been confirmed in four sub-Saharan African countries since 2020, but evidence from Ethiopia is limited to molecular surveys without phenotypic confirmation. We aimed to determine whether ART-R met WHO criteria in Ethiopian Plasmodium falciparum populations during 2024–25, integrating day-3 parasite positivity after artemether–lumefantrine treatment, Pfkelch13 genotyping, and the ring-stage survival assay (RSA) 0–3 h on culture-adapted field isolates. Methods We conducted a prospective, multisite, surveillance study at five sentinel health facilities in Ethiopia (Rama, Werkamba, Mehoni, Bako, and Metehara). Patients aged 6 months or older with uncomplicated P falciparum malaria confirmed by microscopy received artemether–lumefantrine according to bodyweight (six doses during 3 days). Pfkelch13 was genotyped by Nanopore sequencing and Pfhrp2/Pfhrp3 deletions were assessed by quantitative PCR. The RSA 0–3 h was performed on culture-adapted field isolates. Follow-up occurred on days 0 and 3. The main outcome was day-3 parasite positivity rate (defined as microscopically detectable asexual P falciparum parasitaemia on day 3 after initiation of artemether–lumefantrine). This study is registered with ClinicalTrials.gov, NCT07527182 (completed). Findings Patients were enrolled from June 6 to Dec 8, 2024, during the 2024 P falciparum transmission season at all five sentinel sites and from July 1 to Nov 8, 2025, during the 2025 transmission season at Werkamba. 3207 febrile patients were assessed for malaria, of whom 2771 were excluded and 436 (14%) were P falciparum -positive on microscopy. 277 (64%) patients were enrolled, of whom 153 (55%) returned for the day-3 parasitological assessment and 124 (45%) were lost to follow-up. 172 (62%) of 277 patients were male and 105 (38%) were female. The median age was 20·0 years (IQR 10·0–30·0). 243 (88%) had P falciparum monoinfection by PCR and 34 (12%) had P falciparum and Plasmodium vivax co-infections undetected by microscopy at enrolment. The day-3 parasite positivity rate was 19·6% ([95% CI 14·1–26·6] in 30 of 153 patients with available data). 26 (9%) of 277 enrolled patients carried a validated Pfkelch13 mutation and were positive on day 3, exceeding the WHO 5% threshold for confirmation of ART-R. A strong age-dependent gradient was observed in a post-hoc analysis, with six (38%) of 16 patients younger than 5 years, 14 (35%) of 40 aged 5–15 years, and ten (10%) of 97 older than 15 years (p=0·00035). R622I was detected in 143 (53%) samples of 271 genotyped isolates. Carrying an R622I mutation was associated with day-3 positivity (26 [33%] of 79) in a univariate analysis (crude odds ratio [OR] 7·85 [95% CI 2·58–23·91]; p=0·0003). After adjustment, the association remained strong and…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chala, B., Platon, L., Tibiri, Y. N. G., Strubel, P.-E., Thiebaut, L., Wade, A., Caspar, E., Muller, A., Bastien, M., Nigussie, H., Zhang, Q., Cao, J., Lu, F., Piola, P., Mamo, H., Golassa, L., & Ménard, D. (2026). Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00301-4

MLA 9

Chala, Buze, et al. “Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study.” The Lancet Infectious Diseases, 2026. https://doi.org/10.1016/s1473-3099(26)00301-4.

Chicago

Chala, Buze, Lucien Platon, Yssimini Nadège Guillène Tibiri, Pierre-Emeric Strubel, Lucas Thiebaut, Alioune Wade, Emmanuelle Caspar, et al. 2026. “Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study.” The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00301-4.

Harvard

Chala, B. et al. (2026) ‘Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study’, The Lancet Infectious Diseases. doi:10.1016/s1473-3099(26)00301-4.

IEEE

B. Chala et al., “Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study,” The Lancet Infectious Diseases, 2026, doi: 10.1016/s1473-3099(26)00301-4.

BibTeX

@article{chala2026clinical,
  title     = {{Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study}},
  author    = {Chala, Buze and Platon, Lucien and Tibiri, Yssimini Nadège Guillène and Strubel, Pierre-Emeric and Thiebaut, Lucas and Wade, Alioune and Caspar, Emmanuelle and Muller, Allan and Bastien, Marie and Nigussie, Helen and Zhang, Qingfeng and Cao, Jun and Lu, Feng and Piola, Patrice and Mamo, Hassen and Golassa, Lemu and Ménard, Didier},
  journal   = {The Lancet Infectious Diseases},
  year      = {2026},
  doi       = {10.1016/s1473-3099(26)00301-4},
  url       = {https://doi.org/10.1016/s1473-3099(26)00301-4}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control

  • Plasmodium falciparum
  • artemether-lumefantrine
  • Pfkelch13
  • malaria surveillance
  • Ethiopia
  • sentinel sites
  • antimalarial drug resistance
  • field isolates

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Chala, B., Platon, L., Tibiri, Y. N. G., Strubel, P.-E., Thiebaut, L., Wade, A., Caspar, E., Muller, A., Bastien, M., Nigussie, H., Zhang, Q., Cao, J., Lu, F., Piola, P., Mamo, H., Golassa, L., & Ménard, D. (2026). Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00301-4

How many times has this paper been cited?

4 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Infectious Diseases: sign in and open the full text from this page.

Who wrote this paper?

Buze Chala, Lucien Platon, Yssimini Nadège Guillène Tibiri, Pierre-Emeric Strubel, Lucas Thiebaut, Alioune Wade, Emmanuelle Caspar, Allan Muller, Marie Bastien, Helen Nigussie, Qingfeng Zhang, Jun Cao and 5 more.

What is the DOI of this paper?

10.1016/s1473-3099(26)00301-4, permanently at https://doi.org/10.1016/s1473-3099(26)00301-4. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.